3 On the 21st of the month, Shanghai Hanyu Medical Technology Co., Ltd. launched its first overseas product; — " ValveClamp^{® Mitral valve clamp system; Obtained registration approval from the Ministry of Health (MOH) of Indonesia.}

Shanghai Hanyu Medical Technology Co., Ltd; ValveClamp^{® Mitral valve clamp system; Composed of mitral valve clamp, delivery system, and transvalvular valve. The delivery system consists of a conveyor, a pusher, a loader, a catheter sheath, and a dilator. This product does not require cardiac arrest or extracorporeal circulation during surgery, has a small incision, a short surgical approach, and direct positioning; And pure ultrasound-guided intervention ensures that doctors and patients are not affected by X-rays. The tricuspid valve clamp has a large capture range, which is conducive to operation; Adopting a closed loop design, the clamping arms are not easily separated to ensure stable clamping. This product adopts a transapical surgical approach and is suitable for patients with degenerative mitral regurgitation (MR≥ 3+) who have been assessed by a professional cardiac team as having high surgical risk and suitable mitral valve anatomical structure. The underlying diseases of these patients should not affect the clinical benefits of reducing mitral regurgitation.}

Image - ValveClamp® Mitral valve clamp system

With“ Going out to sea; Becoming a key keyword for the development of Chinese enterprises in 2023, Hanyu Medical actively participates in this wave. The approval of Indonesia's listing permit symbolizes the departure of Hanyu Medical's internationalization journey and is of milestone significance. At the same time, Hanyu Medical has also formulated the; The Belt and Road” Heart protecting Journey, Plan to ValveClamp^® Promote to more countries, for“ The Belt and Road” Developing countries along the route bring more accessible and inclusive therapies.